



Ariosa Diagnostics, Inc.
 5945 Optical Court
 San Jose, CA 95138

For Questions:

clientservices@ariosadx.com

US: (855) 927-4672

Intl: +1 (925) 854-6246

Patient and Provider Information

PATIENT NAME:	Jane Doe	ACCOUNT #:	7654321
DATE OF BIRTH:	01/01/1970	CLINIC NAME:	The Clinic Offering Test
MRN:	1234567890123456789	REFERRING/ORDERING CLINICIAN:	Ordering Physician MD
SPECIMEN ID:	AD12345678-PAT	REFERRING/ORDERING CLINICIAN FAX #:	123-456-7890
GESTATIONAL AGE:	10 wks 5 days	OTHER CLINICIAN:	Genetic Counselor MA, CGC
# OF FETUSES:	1	IVF STATUS:	25.0 yr old non-self egg donor
COLLECTION DATE:	01/01/2012	RECEIVED DATE:	01/02/2012
		OTHER CLINICIAN FAX #:	987-654-3210
		REPORT DATE:	01/10/2012


Test Results

CHROMOSOME	RESULT	PROBABILITY	RECOMMENDATION
Trisomy 21 (T21)	HIGH RISK	Greater than 99/100 (99%)	Genetic counseling and additional testing
Trisomy 18 (T18)	Low Risk	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 13 (T13)	Low Risk	Less than 1/10,000 (0.01%)	Review results with patient

18

13

21



TEST DESCRIPTION

The Harmony Prenatal Test is a laboratory developed test that analyzes cell-free DNA (cfDNA) in maternal blood. Directed analysis of cfDNA measures the relative proportion of chromosomes. The test is intended to aid in the risk determination of fetal trisomies 21, 18, and 13 in women with singleton pregnancies of at least 10 weeks gestational age. Trisomy test results incorporate maternal age (or egg donor age) and gestational age-related risk and IVF status provided on the test requisition form.

Probability of aneuploidy is based on cfDNA in blood which may not correlate with fetal genotype. The test is neither intended nor validated for diagnosis or use in cases of multiple pregnancy (e.g. twins), mosaicism, partial chromosomal aneuploidy, and translocations. Not all aneuploid fetuses will be detected, and some euploid fetuses may have "HIGH RISK" results. Results should be considered with other clinical criteria. Results should be communicated with appropriate counseling.

CLINICAL DATA

	Detection Rate	False Positive Rate
T21	>99% (95% CI: 95-100%)	<0.1% (95% CI: 0.0-0.2%)
T18	>98% (95% CI: 93-100%)	<0.1% (95% CI: 0.0-0.3%)

- Given rarity of condition, limited T13 cases analyzed
- Detection rate: 8 of 10 with Harmony
- False positive rate: <0.1% (95% CI: 0.0-0.3%)

Detection and false positive rates based on cut-off of 1/100 (1%)

REFERENCES: Norton ME et al. (2012) Am J Obstet Gyn 207(2):137.e1-8., Nicolaidis KH et al. (2012) Am J Obstet Gyn 207(5):374.e1-6; Ashoor G et al. (2012) Ultrasound Obstet Gynecol [epub ahead of print], data on file

The Harmony Prenatal Test is intended for clinical use and should not be regarded as investigational or for research. It was developed, and its performance characteristics determined, by the Ariosa Diagnostics Clinical Laboratory, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. The test has not been cleared or approved by the U.S. Food and Drug Administration.